Traws Pharma Inc. (TRAW) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Traws Pharma Inc. (TRAW:NASDAQ), powered by AI.

Current Price
$2.18
P/E Ratio
2.0
Market Cap
18M
Sector
Healthcare
What is the Traws Pharma Inc. stock price forecast?

Traws Pharma Inc. is currently trading at $2.18. View real-time AI analysis on Alpha Lenz.

What is Traws Pharma Inc. insider trading activity?

View the latest insider trading data for Traws Pharma Inc. on Alpha Lenz.

What is Traws Pharma Inc.'s P/E ratio?

Traws Pharma Inc.'s P/E ratio is 2.0.

Traws Pharma Inc.

NASDAQ · TRAW
$2.18+0.48(+28.24%)Market closedNASDAQ regular session 09:30–16:00 ET
Ask about Traws Pharma Inc.'s future dividend policy...
Alpha Chat Insight

Traws Pharma Inc. trades at a P/E of 2.0 (undervalued) with modest ROE of -56.9%. 3Y revenue CAGR of 131.1% highlights clear growth momentum.

Ask for details

Company Overview

Traws Pharma Inc. is a distinguished name in the pharmaceutical industry, primarily focused on the research, development, and commercialization of innovative treatments for a diverse range of medical conditions. With a strong commitment to advancing medical science, Traws Pharma operates at the intersection of cutting-edge biotechnology and classic pharmaceutical expertise. Its product pipeline includes groundbreaking therapies targeting oncology, rare genetic disorders, and metabolic diseases, showcasing its adaptability and dedication to addressing complex health challenges. The company plays a significant role in the healthcare sector, contributing to enhanced patient outcomes and pioneering medical advancements. Traws Pharma's collaborations with leading research institutions and its sustainable growth strategies reinforce its place in the market as a forward-thinking entity. As an active player in the global pharmaceutical landscape, it leverages its robust R&D infrastructure and regulatory expertise to bring new treatments to market efficiently. Founded with the mission to improve lives through science, Traws Pharma Inc. is well-regarded for its patient-centric approach and its unwavering focus on quality and efficacy. Its leadership in therapeutic innovation continues to drive significant impact across multiple healthcare domains.

CEODr. Iain D. Dukes DPHIL, M.A., Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees6

Company Statistics

FY 2025

Profile

$17.94MMarket Cap
$2.79MRevenue
0.00Shares Out
6Employees

Margins

N/AGross
-1590.72%EBITDA
-640.68%Operating
328.67%Pre-Tax
328.67%Net

Valuation

1.96P/E
-28.52P/B
6.43EV/Sales
-0.32EV/EBITDA
-0.86P/FCF

Growth (CAGR)

131.12%Rev 3Yr
64.59%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

51.55%ROA
-56.85%ROE
-100.48%ROIC

Financial Health

$3.82MCash & Cash Equivalents
$7.43MNet Debt
-1787.92%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Traws Pharma Inc. (ticker: TRAW) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 6 employees. Market cap is $18M.

The current price is $2.18 with a P/E ratio of 1.96x and P/B of -28.52x.

ROE is -56.85% and operating margin is -640.68%. Annual revenue is $3M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Traws Pharma Inc. (Healthcare) Stock Forecast & Analysis $2.18 | Alpha Lenz